ACAD Financial Facts
Loss from operations: -72.4MCollaborative revenues: 5.27M
See Full Income Statement
See Full Balance Sheet
ACADIA Pharmaceuticals (ACAD) Earnings
|
Expand Research on ACAD
| Next EPS Date | 5/1/24 | EPS Growth Rate | +122.2% |
|---|---|---|---|
| Average EPS % Beat Rate | +22.3% | Revenue Growth Rate | +76.2% |
| Average % Move 1-Wk after EPS | -5.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/9/17 |  |
Q117 | -$0.72 | -$0.73 | +$0.01 | $15.29M | $15.19M | = |  | | Details |
| 5/4/22 | |
Q122 | -$0.70 | -$0.60 | -$0.10 | $115.5M | $121.92M | = | | | Details |
| 2/28/17 | |
Q416 | -$0.65 | -$0.65 | $0.00 | $11.96M | $9.05M | = | | | Details |
8/4/16  |
|
Q216 | -$0.63 | -$0.49 | -$0.14 | $97K | $90K | N/A | | | Details |
| 11/7/16 |
|
Q316 | -$0.61 | -$0.56 | -$0.05 | $5.3M | $2.9M | N/A | | | Details |
| 5/1/19 | |
Q119 | -$0.59 | -$0.52 | -$0.07 | $62.96M | $60.69M |  |
| | Details |
| 5/7/20 | |
Q120 | -$0.57 | -$0.48 | -$0.09 | $90.1M | $91.51M | = | | | Details |
| 8/8/17 | |
Q217 | -$0.55 | -$0.72 | +$0.17 | $30.48M | $20.02M | = | | | Details |
